

WEST

Freeform Search

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

uterotrophic and birth control

Display: **Documents in Display Format:** **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Image

Search History

Today's Date: 11/5/2001

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB,JPAB,EPAB,DWPI	uterotrophic and birth control (tectoridin or tectorigenin) and (dysmennorhea or uterine bleeding or	6	<u>L18</u>
USPT,PGPB,JPAB,EPAB,DWPI	menopaus\$13 or hot flush or climacteric or osteo\$13 or cardio\$13 or angio\$11 or arther\$13 or athers\$13)	7	<u>L17</u>
USPT,PGPB,JPAB,EPAB,DWPI	Iridaceae and (dysmennorhea or uterine bleeding)	0	<u>L16</u>
JPAB,EPAB,DWPI	(l11 or l12 or l13) and (dysmennorhea or uterine bleeding)	0	<u>L15</u>
JPAB,EPAB,DWPI	(l11 or l12 or l13) and (menopaus\$13 or hot flush or climacteric or osteo\$13 or cardio\$13 or angio\$11 or arther\$13 or athers\$13)	1	<u>L14</u>
JPAB,EPAB,DWPI	tectori\$11	16	<u>L13</u>
JPAB,EPAB,DWPI	tectoridin	1	<u>L12</u>
JPAB,EPAB,DWPI	tectorig\$7	8	<u>L11</u>
JPAB,EPAB,DWPI	(17 or l8) and tectorig\$7	1	<u>L10</u>
JPAB,EPAB,DWPI	(17 or l8) and tecotorig\$7	0	<u>L9</u>
JPAB,EPAB,DWPI	17 and (menopaus\$5)	80	<u>L8</u>
JPAB,EPAB,DWPI	hot flush	127	<u>L7</u>
JPAB,EPAB,DWPI	testosterone same alpha\$1reducata inhibitor	0	<u>L6</u>
JPAB,EPAB,DWPI	testosterone 5-alpha reductase inhibitor	1	<u>L5</u>
USPT,JPAB,EPAB,DWPI	testosterone 5-alpha reductase inhibitor	1	<u>L4</u>
USPT,JPAB,EPAB,DWPI	testosterone adj2 alpha reductase inhibitor	1	<u>L3</u>
USPT,JPAB,EPAB,DWPI	testerone alpha reductase inhibitor	0	<u>L2</u>
DWPI,USPT,EPAB,JPAB	testerone 5-alpha reductase inhibitor	0	<u>L1</u>

WEST**End of Result Set**

Generate Collection

L18: Entry 6 of 6

File: USPT

Sep 28, 1999

DOCUMENT-IDENTIFIER: US 5958916 A

TITLE: Dihydronaphthalene and naphthalene compounds,
intermediates, formulations, and methods

BSPR:

The present invention also provides methods for inhibiting estrogen deficient pathologies including, for example, lack of birth control, postmenopausal syndrome including, for example, osteoporosis, cardiovascular disease, restenosis, and hyperlipidemia, certain cancers in men such as prostate cancer, acne, hirsutism, dysfunctional uterine bleeding, dysmenorrhea, and atrophic vaginitis comprising administering to a mammal in need of treatment an effective amount of a compound of formula I, and, optionally, an effective amount of a progestin. One of skill in the art will recognize that estrogenic agents have a multitude of applications for treating estrogen deficient pathologies well beyond those listed infra. The present invention contemplates and encompasses such maladies although not specified by name.

DEPR:

The study would continue for six months, and each the patients would be examined for changes in the above parameters. During the course of treatment, the patients in the treatment group would show a decreased change in the biochemical markers of bone resorption as compared to the control group. Also, the treatment group would show little or no decrease in bone mineral density compared to the control group. Both groups would have similar uterine histology, indicating the compounds of formula I have little or no uterotrophic effects.